An evaluation of the interaction of meloxicam with frusemide in patients with compensated chronic cardiac failure

British Journal of Clinical Pharmacology

Volumn 44, Issue 4, 1997, Pages 393-398

  Muller F O ^a   Middle, M V ^a   Schall, R ^a   Terblanche J ^a   Hundt, H K L ^a   Groenewoud, G ^a  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

Drug interaction; Electrolytes; Frusemide; Meloxicam

Indexed keywords

FUROSEMIDE; MELOXICAM; PLACEBO;

ADULT; AGED; ANKLE EDEMA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIURESIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG INTERACTION; DYSPNEA; FEMALE; HEADACHE; HEART FAILURE; HEARTBURN; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM EXCRETION;

EID: 0030819593     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00586.x     Document Type: Article

References (13)

1. Brater DC. Resistance to loop diuretics. Why it happens and what to do about it. Drugs 1985; 30: 427-443.
2. Müller FO, Schall R, De Vaal AC, Groenewoud G, Hundt HKL, Middle MV. Influence of metoxicam on frusemide pharmacokinetics and pharmacodynamics in healthy volunteers. Eur J Clin Pharmacol 1995; 48: 247-251.
3. Good Clinical Practice for Trials on Medicinal Products in the European Community. In The Rules Governing Medicinal Products in the European Community. Volume III. Addendum, July 1990. Guidelines on the quality, safety and efficacy of medicinal products for human use. Commission of the European Communities, Luxembourg, 1990 57-98.
4. Investigation of Bioavailability and Bioequivalence. In The Rules Governing Medicinal Products in the European Community. Volume III. Addendum no 2. Guidelines on the quality, safety and efficacy of medicinal products for human use. Commission of the European Communities, Luxembourg, 1992; 149-164.
5. max for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol 1991; 29: 394-399.
6. Schall R, Luus HG. Comparison of absorption rates in bioequivalence studies of immediate release drug formulations. Int J Clin Pharmacol Ther Toxicol 1992; 30: 153-159.
7. Brockmeier D, Lückel G. HOEREP-PC (Version 1.05.00). An interactive program package for the analysis of phamacokinetic data. User manual. International report, Document No. 011502, Hoechst AG, Frankfurt/Main 1991.
8. Steinijans VW, Hauschke D. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol 1991; 30: 323-328.
9. Steinijans VW, Diletti E. Statistical analysis of bioavailability studies. Parametric and nonparametric confidence intervals. Eur J Clin Pharmacol 1983; 24: 127-136.
10. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol 1991; 29: 1-8.
11. Walker L, Frölich JC. Renal prostaglandins and leukotrienes. Review of Physiology, Biochemistry and Pharmacology 1987; 107: 1-72.
12. Kulling PEJ, Backman EA, Skagins ASM. Renal impairment after acute diclofenac, naproxen and sulindac overdoses. J Toxicol Clin Toxicol 1995; 33: 173-177.
13. Engelhardt G. Meloxicam, a potent inhibitor of COX-2. Abstract: 9th International Conference on Prostaglandins and Related Compounds. Florence, Italy 6-10 June 1994.